(PharmaNewsWire.Com, April 12, 2019 ) The market growth is primarily driven by increasing government and private funding for stem cell research and technological innovations in stem cell research-based instruments.
The global stem cell assay market is expected to reach USD 1,978.7 Million by 2023 from USD 791.9 Million in 2018, at a CAGR of 20.1%.
The global stem cell assay market is dominated by North America, followed by Europe. North America will continue to dominate the global stem cell assay market in the forecast period.
Moreover, this region is also expected to witness the highest CAGR during the forecast period. North America’s large share and growth can be attributed to the favorable regulatory guidelines in the region, growing awareness about stem cell assays, the presence of a large number of market players, and increasing government investments in the field.
The factors such as the high degree of consolidation and a complex regulatory framework for the approval of new products may restrain the market’s growth to a certain extent.
Major industry players adopted product launches and partnerships & agreements to maintain and improve their position in the stem cell assay market. Thermo Fisher Scientific (US), Merck (Germany), GE Healthcare (US), Bio-Rad Laboratories (US), and Promega Corporation (US) have been identified as key players in this market.
These companies have a broad product portfolio with comprehensive features and have also expanded their presence geographically. These leaders also have products for all end users in this market, a strong geographical presence, and they focus on continuous product innovations.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
